RxSight raises FY26 revenue view to $140M-$160M from $120M-$135M
Consensus $129.24M. The company said that the FY26 revenue view is inclusive of RxSight sales and revenue recognized from the RxSight Alcon Strategic Collaboration, comprised of: Sales of $110M-$120M, below previous guidance of $120M-$135M; Collaboration Agreement revenue of $30M-$40M, subject to the terms and conditions described in the Current Report on Form 8-K filed with the Securities and Exchange Commission on or about the date hereof; Gross margin of 73% to 75%, above previous guidance of 70% to 72%; and Operating expense at the high-end of $150M-$160M, in line with previous guidance.
Consensus $129.24M.
The company said that the FY26 revenue view is inclusive of RxSight sales and revenue recognized from the RxSight Alcon Strategic Collaboration, comprised of: Sales of $110M-$120M, below previous guidance of $120M-$135M; Collaboration Agreement revenue of $30M-$40M, subject to the terms and conditions described in the Current Report on Form 8-K filed with the Securities and Exchange Commission on or about the date hereof; Gross margin of 73% to 75%, above previous guidance of 70% to 72%; and Operating expense at the high-end of $150M-$160M, in line with previous guidance.